Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Simula

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Tissue Antigens|August 17, 2005
Identification of a novel human DRB1*13 allele by sequence-based DRB typingL Caggiari, M P Simula, A Marzotto, et al.
Journal of Endocrinological Investigation|July 20, 2021
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitorsR Rodia, F Pani, G Caocci, et al.
Clinical and Experimental Immunology|March 6, 2007
Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cellsV De Re, M P Simula, L Caggiari, et al.
Rheumatology (Oxford, England)|January 10, 2006
Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analysesV De Re, S De Vita, D Sansonno, et al.
Leukemia|April 18, 2006
HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferationsV De Re, D Sansonno, M P Simula, et al.
Leukemia|March 16, 2007
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacyM P Simula, S Marktel, C Fozza, et al.
Bone Marrow Transplantation|July 28, 2009
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMTY Chalandon, J R Passweg, C Schmid, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Tissue Antigens|August 17, 2005
Identification of a novel human DRB1*13 allele by sequence-based DRB typingL Caggiari, M P Simula, A Marzotto, et al.
Journal of Endocrinological Investigation|July 20, 2021
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitorsR Rodia, F Pani, G Caocci, et al.
Clinical and Experimental Immunology|March 6, 2007
Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cellsV De Re, M P Simula, L Caggiari, et al.
Rheumatology (Oxford, England)|January 10, 2006
Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analysesV De Re, S De Vita, D Sansonno, et al.
Leukemia|April 18, 2006
HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferationsV De Re, D Sansonno, M P Simula, et al.
Leukemia|March 16, 2007
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacyM P Simula, S Marktel, C Fozza, et al.
Bone Marrow Transplantation|July 28, 2009
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMTY Chalandon, J R Passweg, C Schmid, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Pageof 1